Kala Pharmaceuticals Inc
$ 0.23
1.30%
14 Apr - close price
- Market Cap 205,778,000 USD
- Current Price $ 0.23
- High / Low $ 0.23 / 0.21
- Stock P/E N/A
- Book Value -1.17
- EPS -5.64
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.66 %
- ROE -7.08 %
- 52 Week High 20.60
- 52 Week Low 0.14
About
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of therapies using its proprietary nanoparticle-based mucus penetrating particle (MPP) technology for the treatment of eye diseases. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$1.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-19 | 2025-08-08 | 2025-05-12 | 2025-03-27 | 2024-11-11 | 2024-08-06 | 2024-05-14 | 2024-03-29 | 2023-11-13 | 2023-08-04 | 2023-05-09 | 2023-03-03 |
| Reported EPS | -1.07 | -1.71 | -1.7414 | -1.2316 | -1.9341 | -3.16 | -4.19 | -3.18 | -3.41 | -4.36 | -6.99 | -7.97 |
| Estimated EPS | -2.81 | -2.93 | -2.54 | -2.47 | -2.43 | -4.4 | -2.89 | -3.62 | -2.15 | -3.19 | -4.52 | -6.55 |
| Surprise | 1.74 | 1.22 | 0.7986 | 1.2384 | 0.4959 | 1.24 | -1.3 | 0.44 | -1.26 | -1.17 | -2.47 | -1.42 |
| Surprise Percentage | 61.9217% | 41.6382% | 31.4409% | 50.1377% | 20.4074% | 28.1818% | -44.9827% | 12.1547% | -58.6047% | -36.6771% | -54.646% | -21.6794% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KALA
2026-04-02 13:10:15
This page provides a comprehensive resource for Kala Pharmaceuticals (KALA) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading information. It offers AI-powered summaries of these documents to help investors understand the company's financial status, pipeline programs like KPI-012, and strategic decisions. Recent filings cover events such as the 2025 annual meeting schedule, ownership disclosures by Point72 and Perceptive Advisors, executive stock options, CEO appointment, and Q2 2025 financial results.
2026-04-02 07:09:39
This page on Stock Titan provides comprehensive access to Kala Pharmaceuticals Inc. (NASDAQ: KALA) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material event reports (8-K), and insider trading forms (Form 4). It highlights the company's focus on rare eye diseases, its MSC-S platform, and financial developments, with AI-powered summaries to help interpret the documents. Recent filings detail planned stock sales by executives and a director, primarily to cover tax withholding obligations related to RSU vesting.
2026-03-22 07:39:18
This article analyzes the historical performance of investing $1,000 in Kala Pharmaceuticals Inc (KALA) over various periods, showing significant losses for investors. It details the company's shift in focus after a failed clinical trial for KPI-012, its financial restructuring including debt settlement and new financing, and its efforts to explore strategic alternatives for its product candidates and intellectual property. The analysis highlights KALA's status as a clinical-stage biopharmaceutical company focused on rare ocular diseases, currently undergoing a period of strategic evaluation and capital restructuring.
2026-03-13 18:39:43
Morgan Stanley Smith Barney LLC has submitted a Form 144 to report proposed sales of restricted Common Stock of Kala Pharmaceuticals (NASDAQ: KALA). The filing details multiple restricted-stock lots with various grant/vesting dates and share counts, indicating an intent to sell under Rule 144. This notice is procedural and does not confirm actual sales, aggregate proceeds, or buyer details, with market impact depending on future execution.
2026-03-11 06:30:00
KALA BIO (NASDAQ: KALA), rebranded as Researgency.ai, is launching its first commercial AI agent in approximately 14 days, transforming the company into a dual-engine entity combining its drug pipeline with a scalable AI platform. This strategic pivot targets the projected $180+ billion AI-in-healthcare market by 2030, aiming to automate complex and time-sensitive workflows in biotech. The market reacted positively, with KALA's stock gaining significantly following the announcement.
2026-03-07 02:10:27
KALA BIO announced a strategic initiative to deploy an on-premises, data-sovereign AI infrastructure for the biotech industry, securing an exclusive 12-month license for the "Researgency" platform from Younet AI. This platform will initially be used internally on KALA's MSC-S datasets and KPI-012 program, with plans for external licensing to other biotech and pharma companies after validation. The company aims to provide institutional-grade AI to the biotech industry without requiring clients to surrender control of their proprietary data, addressing a significant market need for secure AI solutions.
